UPC Analytics
ENDE
Overview · Filed:

ACT_16112/2024

NOVEL ANTITUMORAL USE OF CABAZITAXEL

InfringementMain Infringement ActionMunich LDInfringement Action
  • 2025-09-15Procedural onlyproceduralInfringement Action

    The Munich Local Division issued a post-interim-conference procedural order in consolidated infringement actions by Sanofi (and successor entities) against multiple generic companies (Accord, STADA, Dr Reddy's, Zentiva) relating to EP 2 493 466 (UPC_CFI_145–503/2024 group). The order confirmed oral hearing dates (14–17 October 2025) and directed that the four counterclaims for revocation be heard together while each infringement action is heard separately.